Tweet News Multiple sclerosis: Could Roche’s bestselling drug Ocrevus be doing more harm than good in women with primary progressive MS? BMJ 2026; 393 doi: https://doi.org/10.1136/bmj.s666 (15 April 2026) Cite this as: BMJ 2026;393:s666 Neurological drugs have been in the media over the last couple of days. There is a report that Alzheimer drugs are not good enough and it has been…
Meeting Abstracts are they a load of old biased cobblers?
Tweet This paper is perhaps interesting as we go into AAN week…All that will surface for the masses is the Conference abstract. For AAN they will all be published in the Journal Neurology, just as ECTRIMS abstracts are published in the Multiple Sclerosis Journal. The question here is whether abstracts published in meetings are biased…
MS treatment during pregnancy found safe for babies’ brain growth
Using disease-modifying treatments shortly prior to or during pregnancy does not seem to increase the risk of neurodevelopmental disorders in exposed children, according to a real-world study of mothers with multiple sclerosis (MS). Still, sphingosine-1-phosphate (S1P) receptor modulators, which include therapies such as Gilenya (fingolimod), Mayzent (siponimod), and Ponvory (ponesimod), were linked to an increased…
A springtime downpour brings back memories of my biggest supporter
As I write this, the April showers that bring May flowers have brought forth a string of gloomy days here in central Texas. During days like these, I cannot help but be reminded of my grandma, who passed away about a year ago after a battle with dementia. I remember my childhood spent in her…
Well Well Wellness
By Angel Blair When it comes to wellness and how we take care of our minds and bodies, there’s definitely some leeway as to what works for each person and what type of wellness is being referred to. If we’re … Continue reading → Source: blog.mymsaa.org
New blood test may help track MS disease between relapses
A blood test being developed by Roche to measure a marker of nerve cell damage has received CE mark approval for the detection of neuroinflammation in people with relapsing-remitting multiple sclerosis (RRMS). Called Elecsys Neurofilament Light Chain (NfL), the test is designed to measure NfL levels, which are increased in many neurological conditions due to…
Counting cell in blood as a predicitve factor for disease activity
Tweet This paper argues that if you look at blood cell counts it may help about look at disease activity. This view is perhaps abit controversial as there have been many studies looking at immune cell subsets circulating in the blood after a DMT and have not been able to find an association with disease…
Nearly 60% higher risk of MS seen for people with diabetes in new study
People with diabetes are significantly more likely — with nearly 60% higher odds — to develop multiple sclerosis (MS) than those without the metabolic disease, which is marked by high blood sugar levels, according to a new systematic review and meta-analysis. A significant association was also observed specifically between type 2 diabetes, the most common…
MS caregiving is an emotional roller coaster I didn’t anticipate
I was outside with my youngest child, who was only a few months old, strapped to my back while doing yard work, housework, and everything else, while my husband, Rhead, lay on the couch inside. This had been going on for a couple of years by then. Slowly, without a clear explanation, the weight of…
New owner to offer PoNS device used for walking, balance in MS
The portable neuromodulation stimulator (PoNS), a noninvasive device that’s approved to improve walking and balance in people with multiple sclerosis (MS), has been acquired by Bioness Medical. The device was originally developed by Helius Medical Technologies, which rebranded to Solana in September of last year as it pivoted away from its neurotechnology business. Bioness has…